Press Releases Formycon AG Börse Stuttgart

Equities

FYB

DE000A1EWVY8

Real-time Estimate Tradegate Other stock markets 01:48:40 03/06/2024 pm IST			5-day change	1st Jan Change
45.08 ^EUR	+2.33%		+5.26%	-20.77%

25/04	Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI
18/03	Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders	16/05	AQ
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region	15/05	EQ
Formycon reports on successful operating business and financial figures for the first quarter of 2024	08/05	EQ
Formycon invites to the Annual General Meeting on June 12, 2024 in Munich	07/05	EQ
Formycon hosts conference call on the results of the first quarter 2024	02/05	EQ
DD: Formycon AG: Dr. Marc Mikulcik, buy	30/04	EQ
Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance	25/04	EQ
DD: Formycon AG: Dr. Stefan Glombitza, buy	24/04	EQ
MDL Panel Grants Transfer Of Aflibercept BPCIA Case	22/04	AQ
Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024	22/04	EQ
Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast	13/04	EQ
Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year	12/04	EQ
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)	11/04	EQ
Fresenius Kabi And Formycon Reach Settlement Agreement For Ustekinumab Biosimilar Candidate In Europe And Canada	03/04	AQ
Updates On Aflibercept BPCIA Litigation	26/03	AQ
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada	18/03	EQ
FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region	11/03	EQ
Updates On Aflibercept BPCIA Litigation	19/02	AQ
Gedeon Richter becomes strategic investor of Formycon via equity investment	30/01	EQ
Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor	30/01	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Formycon AG Börse Stuttgart

Equities

FYB

DE000A1EWVY8

Press Releases

Filters